Petros Grivas, MD, PhD: Overview of NIAGARA Trial Data for Muscle Invasive Bladder Cancer
Petros Grivas, MD, PhD, of the University of Washington and Fred Hutch Cancer Center, reviewed the data from the Phase 3 NIAGARA trial, which demonstrated that adding durvalumab to neoadjuvant gemcitabine and cisplatin (GC) chemotherapy, followed by adjuvant durvalumab, significantly prolonged event-free and overall survival in cisplatin-eligible patients with localized muscle invasive bladder cancer.